Biomarker-Based Immunoassays Market Size Worth USD 8.86 Billion by 2034 | CAGR: 5.3%

The biomarker-based immunoassays market size is expected to reach USD  8.86 Billion by 2034, according to a new study by Polaris Market Research. The report “Biomarker-Based Immunoassays Market Share, Size, Trends, Industry Analysis Report: By Sample Type, By Product, By Biomarker Type, By Disease Indication, By End User, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Biomarker-based immunoassays provide reliable tools for early disease detection, monitoring, and personalized treatment across chronic and age-related conditions. These solutions include reagents, kits, instruments, and services, supporting hospitals, diagnostic laboratories, and research institutes with accurate, efficient, and scalable testing options.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/biomarker-based-immunoassays-market/request-for-sample

Market growth is driven by rising prevalence of chronic diseases, increasing routine biomarker testing, and growing healthcare expenditure. Moreover, adoption of multiplex assays, AI-assisted analysis, and point-of-care testing enhances diagnostic accuracy, patient outcomes, and clinical efficiency globally.

Biomarker-Based Immunoassays Market Report Highlights

• Based on sample type, blood samples dominated in 2024, driven by widespread clinical adoption and standardized protocols.
• In terms of product, the reagents & kits dominated in 2024 driven by high demand for assay components.
• Based on biomarker type, the predictive & prognostic biomarkers dominated in 2024 due to their role in treatment selection.
• In terms of disease indication, the cancer dominated in 2024 due to high prevalence and demand for early detection.
• Based on end user, hospitals dominated in 2024, fueled by high patient volumes and advanced diagnostic infrastructure.
• North America dominated in 2024, backed by strong healthcare systems and government support for chronic disease management.
• Asia Pacific projected fastest CAGR, fueled by expanding diagnostic networks, rising chronic disease prevalence, and improving healthcare accessibility.
• Key players in the global market include Abbott Laboratories, Thermo Fisher Scientific Inc., Siemens Healthineers, Roche Diagnostics, Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Merck KGaA, Agilent Technologies, Inc., Fujirebio, Quanterix, EKF Diagnostics, and Quibim.

Polaris Market Research has segmented the market report based on sample type, product, biomarker type, disease indication, end user, and region:

By Sample Type Outlook (Revenue, USD Billion, 2020–2034)

• Blood
• Tissue
• Urine
• Saliva
• Others

By Product Outlook (Revenue, USD Billion, 2020–2034)

• Reagent & Kits
• Consumables
• Instruments/Analyzers
• Services

By Biomarker Type Outlook (Revenue, USD Billion, 2020–2034)

• Efficacy & Pharmacodynamic Biomarkers
• Safety & toxicity biomarkers
• Predictive & Prognostic Biomarkers
• Surrogate/Exploratory Biomarkers

By Disease Indication Outlook (Revenue, USD Billion, 2020–2034)

• Cancer
• Cardiovascular Diseases
• Neurological Diseases
• Immunological Diseases
• Other Diseases

By End User Outlook (Revenue, USD Billion, 2020–2034)

• Hospitals & Clinics
• Diagnostic Laboratories
• Research & Academic Institutes
• Other End Users

By Regional Outlook (Revenue, USD Billion, 2020–2034)

• North America

• US
• Canada

• Europe

• Germany
• France
• UK
• Italy
• Spain
• Netherlands
• Russia
• Rest of Europe

• Asia Pacific

• China
• Japan
• India
• Malaysia
• South Korea
• Indonesia
• Australia
• Vietnam
• Rest of Asia Pacific

• Middle East & Africa

• Saudi Arabia
• UAE
• Israel
• South Africa
• Rest of Middle East & Africa

• Latin America

• Mexico
• Brazil
• Argentina
• Rest of Latin America